DUBLIN--(BUSINESS WIRE)--The "Transthyretin Amyloidosis (ATTR) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
The total diagnosed prevalent population of Transthyretin Amyloidosis (ATTR) was found to be 19,160 in the year 2016 in 7MM.
Transthyretin Amyloidosis (ATTR) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ATTR in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Transthyretin Amyloidosis (ATTR) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The current therapeutic market is dominated by the use of symptomatic therapies. Liver Transplantation is disease-modifying treatment for patients with Hereditary Transthyretin Amyloidosis, while Carpal tunnel release surgery is recommended for the treatment of Carpal Tunnel Syndrome among the patients. Vyndaqel (Tafamidis) by Pfizer, is a specific and potent TTR stabilizing compound approved for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic Polyneuropathy in Europe and for all stages in Japan.
Detailed chapter for upcoming therapies like CRX-1008 (Corino Therapeutics Inc.), Inotersen (Ionis Pharmaceuticals Inc.), and Patisiran (Alnylam Pharmaceuticals) have also been covered in the report.
Key Topics Covered:
1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
4. Epidemiology and Patient Population
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
8. Unmet Needs
9. Marketed Drugs
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
13. Phase II Drugs
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
17. Market Drivers
18. Market Barriers
- Corino Therapeutics Inc.
- Ionis Pharmaceuticals Inc.
- Pfizer Inc.
- Alnylam Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/q2gstz/transthyretin?w=4